Lilly, Alkermes end partnership on inhaled insulin

Eli Lilly and Co. says it is ending its partnership with biotech firm Alkermes to develop AIR Insulin, an inhaled insulin product. Two other companies, Pfizer and Novo Nordisk A/S, have also said they would discontinue trials of similar drug candidates. Alkermes said that the withdrawal was not due to safety or efficacy concerns, while a Lilly spokesman cited "new uncertainties in the regulatory environment" as a factor in its decision.

View Full Article in:

Wall Street Journal (free content), The · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA